This concluding chapter critically discusses the implications, strengths, and limitations of the machine learning methodologies developed for nanomedicine screening throughout the manuscript. It highlights the transformative potential of ML-driven virtual screening for rapidly identifying and optimizing mRNA-based therapeutics, emphasizing reductions in developmental timelines, experimental resources, and costs. Practical considerations are thoroughly addressed, including ethical concerns related to patient data privacy, transparency in AI model implementation, and regulatory challenges. The chapter candidly evaluates limitations inherent to data-driven approaches, notably data scarcity, variability in biological systems, and model transferability. It outlines future research avenues, including the integration of larger, heterogeneous datasets, the exploration of deep learning and transfer learning models, and the incorporation of real-world patient data. The chapter concludes by underscoring the strategic combination of ML, chemoinformatics, and biological domain expertise as critical for advancing precision medicine in oncology and beyond.